Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
  • Medical Education
      • All Therapeutic Areas
      • Dermatology
        • Diabetes
        • Hypoglycemia
      • Gastroenterology
      • Infectious Disease
      • Neuroscience
      • Oncology
      • Rheumatology
      • Tools for Communication
      • All Therapeutic Areas
      • Dermatology
        • Diabetes
        • Hypoglycemia
      • Neuroscience
      • Oncology
      • Osteoporosis
      • Rheumatology
      • Well-Being
  • Chat Contact Us

Understanding Bruton Tyrosine Kinase (BTK) Pathway Inhibition in B-cell Malignancies​

This slide deck provides information on covalent and reversible (non-covalent) BTK inhibition in the treatment of B-cell malignancies, and a growing unmet need of resistance to covalent BTK inhibition.

Download PDF Download the PDF Document Medical Answer PDF Document Created with Sketch. Understanding Bruton Tyrosine Kinase (BTK) Pathway Inhibition in B-cell Malignancies​

Date of Last Review: May 16, 2022

Are you satisfied with this content?
  • Copyright
  • Terms of Use
  • Privacy Statement
  • Accessibility Statement
  • Sitemap

To speak to customer support:
Call (XXX) XXX-XXXX

This site is intended for US Healthcare Professionals only.

4.0.1 06/2022 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2022. All rights reserved.

Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

Facebook Twitter
Lilly